课题基金 / 基金详情

Exploring the therapeutic potential of combined inhibition of MNK1/2 and CDK4/6 to treat melanoma.

Exploring the therapeutic potential of combined inhibition of MNK1/2 and CDK4/6 to treat melanoma.
探索联合抑制 MNK1/2 和 CDK4/6 治疗黑色素瘤的治疗潜力。
批准号：
461155
负责人：
Miller Wilson H
金额：
$61.3万
依托单位：
Lady Davis Institute for Medical Research (Mtl)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-03-01 至 2027-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=461155&lang=en
关键词：
Immunotherapy Kinase Inhibitors Melanoma Proteomics Tumor Immune Microenvironment

项目摘要

项目成果

Miller Wilson H的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Drugs that activate the immune system have provided dramatic improvements in response and overall survival to a growing number of deadly malignancies. Unfortunately, these therapies do not work in all patients. We have studied how small molecules that inh
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting the Mnk/eIF4E axis in the tumor microenvironment of pregnancy associated breast cancers.
Understanding the role of the MNK-eIF4E axis in the response and resistance to BRAF inhibitors.
Mechanisms of response and resistance to epigenetic therapy in hematological malignancy
Targeting the eukaryotic translation initiation factor eIF4E with ribavirin in breast cancer
海外基金